GSK is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer drug as ...
GSK (NYSE:GSK) is beginning to show a more assertive shift in strategy as CEO Luke Miels pushes the company toward higher-risk oncology development, with plans to launch five simultaneous late-stage ...
(Alliance News) - GSK PLC on Wednesday said it has completed the acquisition of Canada-based clinical stage biopharmaceutical ...
By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has ...
Aragen unveils ChemiSHE, a woman-led lab in Hyderabad, aiming to boost gender diversity with 800+ hires in science and ...
Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...
The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...
Mocertatug rezetecan is an antibody-drug conjugate which targets the B7-H4 antigen. GSK acquired worldwide commercialisation rights, excluding mainland China, Hong Kong, Macau and Taiwan, from Hansoh ...
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late--stage development, global regulatory and operational expertise as MinervaX enters its next phase of ...
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...
GSK's Mocertatug Rezetecan (Mo-Rez) has shown positive early results in treating ovarian and endometrial cancers, shrinking ...
GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results